“…While P450 isoforms in the CYP1, CYP2 and CYP3 subfamilies are generally more regarded for their roles in xenobiotic metabolism, a number of these enzymes have also been evaluated as possible drug targets. Both CYP1A1 and CYP1B1 have been shown to activate procarcinogens as well as to catalyze the metabolism of estrogen and 17β-estradiol (Napoli et al, 2005) with the prevalence of various cancers (Watanabe et al, 2000;Androutsopoulos et al, 2009;Gajjar et al, 2012;Rodriguez and Potter, 2013;Alsubait et al, 2020;Al-Saraireh et al, 2021;Yuan et al, 2022). While much of the research surrounding CYP1A1 and CYP1B1 as therapeutic targets has centered on their ability to activate prodrugs, additional approaches including chemical inhibitors, immunotherapy and antisense oligonucleotides have all been described in the literature (McFadyen and Murray, 2005;Luby, 2008;Mescher and Haarmann-Stemmann, 2018;Carrera et al, 2020).…”